Nyrada (ASX:NYR) FCF Yield % : -37.34 (As of May. 22, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Nyrada FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Nyrada's Trailing 12-Month Free Cash Flow is A$-4.69 Mil, and Market Cap is A$12.56 Mil. Therefore, Nyrada's FCF Yield % for today is -37.34%.

The historical rank and industry rank for Nyrada's FCF Yield % or its related term are showing as below:

ASX:NYR' s FCF Yield % Range Over the Past 10 Years
Min: -256.38 Med: 0 Max: 0
Current: -37.34

ASX:NYR's FCF Yield % is ranked worse than
70.69% of 1556 companies
in the Biotechnology industry
Industry Median: -14.16 vs ASX:NYR: -37.34

Nyrada's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

Nyrada FCF Yield % Historical Data

The historical data trend for Nyrada's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada FCF Yield % Chart

Nyrada Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Yield %

-22.42

-5.56

-13.91

-164.80

Nyrada Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Yield %	Get a 7-Day Free Trial			-13.40	-3.98	-13.92	-257.54	54.54

Competitive Comparison of Nyrada's FCF Yield %

For the Biotechnology subindustry, Nyrada's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nyrada's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nyrada's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Nyrada's FCF Yield % falls into.

Nyrada FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Nyrada's FCF Yield % for the fiscal year that ended in Jun. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-7.199	/	4.368252
	=	-164.80%

Nyrada's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	0.936	*	2	/	3.432198
	=	54.54%

Nyrada FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Nyrada FCF Yield % Related Terms

Thank you for viewing the detailed overview of Nyrada's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nyrada (ASX:NYR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072

Website

https://www.nyrada.com

Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines